title: Effect of dipeptidyl peptidase-IV (DPP-IV) inhibitor (Vildagliptin) on peripheral nerves in streptozotocin-induced diabetic rats.
abstract: OBJECTIVE
  The aim of this study was to investigate the GLP-1 pathway effect on peripheral nerves using a DPP-IV inhibitor in streptozotocin (STZ)-induced diabetic rats.
  
  
  METHODS
  Adult male Sprague Dawley rats were divided into four groups and two groups (n=6 in each) were given a DPP-IV inhibitor of 0.3mg/kg/day or 10mg/kg/day dissolved in water. Intraepidermal innervation was quantified as nerve fiber abundance per unit length of epidermis (IENF/mm) following an immunohistochemical procedure using the polyclonal antibody of anti-protein gene product 9.5 (PGP 9.5).
  
  
  RESULTS
  Daily administration of DPP-IV inhibitor to the experimental diabetes model at doses of 10mg/kg for 32 weeks protected nerve fiber loss compared with untreated rats as follows (IENF/mm): normal (9.89+/-0.34), diabetes mellitus (DM) (8.42+/-0.28), DM with 0.3mg/kg DPP-IV inhibitor (9.88+/-0.38), and DM with 10mg/kg DPP-IV inhibitor (10.36+/-0.32) (p<0.05). There was a significant reduction (% change) in the decrease of intraepidermal nerve fiber density (IENFD) in the DPP-IV inhibitor-treated groups during the experimental period: normal (10.1%), DM (25.8%), DM with 0.3mg/kg DPP-IV inhibitor (13.3%), and DM with 10mg/kg DPP-IV inhibitor (7.9%) (p<0.05).
  
  
  CONCLUSIONS
  Our study suggests that a DPP-IV inhibitor may prevent peripheral nerve degeneration in a diabetes-induced animal model and support the idea that GLP-1 may be useful in peripheral neuropathy.
authors.affiliation: Department of Internal Medicine, Research Institute of Clinical Medicine, Chonbuk National University Medical School, Jeonju, South Korea.
authors.forename: Heung Yong
authors.initials: HY
authors.lastname: Jin
authors.forename: Wei Jing
authors.initials: WJ
authors.lastname: Liu
authors.forename: Ji Hyun
authors.initials: JH
authors.lastname: Park
authors.forename: Hong Sun
authors.initials: HS
authors.lastname: Baek
authors.forename: Tae Sun
authors.initials: TS
authors.lastname: Park
mesh_terms: D000218:Adamantane / Q000031:analogs & derivatives* / Q000494:pharmacology; D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D001835:Body Weight; D003921:Diabetes Mellitus, Experimental / Q000150:complications / Q000473:pathology*; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000494:pharmacology*; D004435:Eating; D004558:Electric Stimulation; D004817:Epidermis / Q000294:innervation; D052216:Glucagon-Like Peptide 1 / Q000097:blood; D006801:Humans; D007328:Insulin / Q000097:blood; D008297:Male; D009410:Nerve Degeneration / Q000209:etiology / Q000473:pathology; D009570:Nitriles / Q000494:pharmacology*; D010525:Peripheral Nerves / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D011759:Pyrrolidines / Q000494:pharmacology*; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D043222:Ubiquitin Thiolesterase / Q000235:genetics / Q000378:metabolism; D000077597:Vildagliptin
chemical_list: D001786:Blood Glucose; D054873:Dipeptidyl-Peptidase IV Inhibitors; D007328:Insulin; D009570:Nitriles; D011759:Pyrrolidines; D052216:Glucagon-Like Peptide 1; C489034:UCHL1 protein, rat; D043222:Ubiquitin Thiolesterase; D000077597:Vildagliptin; D000218:Adamantane